BIO CEO and Investor ConferenceFebruary 10, 2009

Sylvie Grégoire President, Shire HGT

2

THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

3

Product Information

Today’s presentation include information about certain products that are not approved for marketing in the United States. This information is for investor purposes only, and should not be relied upon by health care professionals. It is intended to be informative with respect to Shire HGT’s pipeline, and is not in any way intended to be promotional in nature.

4

Shire Purpose Statement

We enable people with life-altering conditions to

lead better lives.

5

Shire HGT Business Model SupportsStrong Growth

Rare diseases with unmet need

High impact Rx / high margin products

Global development / commercialization

3 Marketed products

Pipeline gaps filled

8 potential launches by 2015

#1 or #2 in our markets

Growth via internal Research and BD

Strong RoW growth with minimal infrastructure

BUSINESSMODEL

PORTFOLIOSTRENGTH

FUTUREGROWTH

6

Orphan Disease Landscape ProvidesSignificant Opportunities for Development

Infectious Diseases

9%

Neuro logical Disorders

11%Other

11%

Cancer and related

47%

Transplantation2%Cardiovascular

Diseases2%

Blood Disorders

1%

Respiratory Disorders

4%

Auto immune Disorders

5%

Genetic Disorders

8%

~ 7,000 orphan diseases

Individually rare but collectively affect 1 in 10

25 million Americans

25-30 million EU

50% Pediatric

85% Serious or life-threatening

7

Long Term Ratios Reflect R&D Investment with Minimal Commercial Infrastructure

Spec Pharma HGT Total Spec Pharma HGT TotalTotal sales % 85% 15% 100% 70% 30% 100%

Gross Margin 85% 89% 86% 86% 87% 86%

R&D (14%) (47%) (19%) (14%) (25%) (17%)

S&M (37%) (19%) (35%) (31%) (16%) (26%)

G&A - - (11%) - - (9%)

EBITDA Margin 34% 23% 21% 41% 46% 34%

2007 TARGET

Note: All expense ratios are a percentage of product sales

8

HGT’s Global Revenue Diversification Meets Corporate Milestone in 2008

2015 Total: $1,706

U.S.A Revenue, 17%

EU5 + Canada Revenue, 42%

RoW Revenue, 41%

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

2008 Total: $505

U.S.A Revenue, 15%

EU5 + Canada Revenue, 60%

RoW Revenue, 25%

0%

10%

20%

30%

40%

50%

60%

70%

USA Revenue20%

RoW Revenue40%

EU5 + CanadaRevenue 40%

USA Revenue15%

EU5 + CanadaRevenue 60%

RoW Revenue25%

9

CommercialPh II/IIIPh I/IIPreclinical IND Tox

POC

HGT Pipeline in October 2007

REPLAGAL®Fabry Disease

ELAPRASE®Hunter Syndrome

VelagluceraseGaucher Disease

HGT 2310 Idursulfase-IT/Hunter CNSHGT 1410 Sanfilippo ERT

HGT 1110MLD ERT

Marketed Product Support

Grow ERT Franchise

New Technology: CNS Diseases

Research

10

CommercialPh II/IIIPh I/IIPreclinical IND Tox

POC

HGT Pipeline Gaps Filled Through Recent BD and Research Success

REPLAGAL®Fabry Disease

ELAPRASE®Hunter Syndrome

VelagluceraseGaucher Disease

HGT 2310 Idursulfase-IT/Hunter CNSHGT 1410 Sanfilippo ERT

HGT 1111MLD ERT

HGT 3310 (AMIGAL™)Fabry Disease

HGT 3410 (PLICERA™)Gaucher Disease

HGT 3510 (AT2220)Pompe Disease

Marketed Product Support

Grow ERT Franchise

New Platform: Pharmacological

Chaperones

New Technology: CNS Diseases

Research

Expand pipeline through Internal Research Capability

New in past 12 mo

HGT 2610Krabbe/GLD ERT

FIRAZYR®*HAE

Expansion to New Products and Targets

* Shire owns a 98% interest in Jerini AG; FIRAZYR® is a registered trademark of Jerini AG

11

Prioritization CriteriaRare Diseases

• Competition• Proof of Concept• Development Feasibility• IP/Exclusivity

• Prevalence• Unmet Need• Commercial Fit

Selecting Products for In-Licensing/Acquisition

Disease Criteria

Product Criteria

Business Development Opportunities

12

Shire HGT- Key Strengths

Fully integrated business, exclusively focused on rare diseases

Global reach – development, regulatory, commercial

Demonstrated success in bringing rare disease products to market

Simultaneous global filings; early market access

Setting new standards for MPS launches with ELAPRASE®

Combine entrepreneurial culture with sufficient resources to achieve success

Why we are a good partner

Replagal

67

14

Fabry Market Continues to Demonstrate Strong Growth

Source: EvaluatePharma

$0

$100

$200

$300

$400

$500

$600

$700

2001 2002 2003 2004 2005 2006 2007

$M

2001-2007 CAGR 99%

Elaprase

72

16

Manage New Patient Accruals

Early TX and CNS Patients

Maintain Compliance

Geographic expansion

Customer Service Model

Focus on early treatment

Published case studies

HOS working groups

Hunter-CNS program

Persistency programs

Publish Long Term Clinical Data

77

18Efficacy

Goal: To establish FIRAZYR as a new global standard of care for HAE patients

Safety Convenience

Treats attacks quickly

Treats all kinds of attacks

Not a “blood derived”product

Not immunogenic

Pre-filled “Ready toUse” Syringe

Subcutaneous dosing

Room temp storage

19

HGT Revenue Growth Reflects Launch of 8 New Products*

20112008 20102009 2012 - 2015

*Subject to regulatory approvals

REPLAGAL

ELAPRASE

FIRAZYR

velaglucerase

MLD/1111

AMIGAL

Pompe/3510

PLICERA

Hunter CNS

Sanfilippo/1410

REPLAGAL

ELAPRASE

FIRAZYR

velaglucerase

MLD/1111

REPLAGAL

ELAPRASE

FIRAZYR

velaglucerase

REPLAGAL

ELAPRASE

FIRAZYR

REPLAGAL

ELAPRASE

FIRAZYR

Krabbe/2610

20

Shire HGT Positioned for Strong Growth

LYSOSOMALSTORAGEDISEASES

LYSOSOMALSTORAGEDISEASES

LYSOSOMALSTORAGEDISEASES

RAREGENETIC

DISEASES

RAREGENETIC

DISEASES

ORPHANDISEASESShir

e HGT’s F

uture Gr

owth

21

To be as brave as the people we help.

Questions

23

HGT Key Criteria for Long Term Revenue Growth

REPLAGAL® - approved in 44 countriesELAPRASE® - approved in 43 countriesFIRAZYR® - approved in 30 countries

HGT Pipeline:velaglucerase alfaHGT-1111 (MLD)AMIGAL (ex-US)PLICERA (ex-US)HGT- 3510 (Pompe, ex-US)HGT-1410 (Sanfilippo-A)HGT- 2310 (Hunter-CNS)HGT-2610 (Krabbe)

Strong IP/Orphan

Speed of Registration

Premium Pricing

High Levels of Reimbursement

Unmet Niche Markets

Symptomatic Disease

Global infrastructure

HGT Global Products